| Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers A Cavalli, E Poluzzi, F De Ponti, M Recanatini Journal of medicinal chemistry 45 (18), 3844-3853, 2002 | 498 | 2002 |
| Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview F De Ponti, E Poluzzi, A Cavalli, M Recanatini, N Montanaro Drug Safety 25 (4), 263-286, 2002 | 389 | 2002 |
| QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development M Recanatini, E Poluzzi, M Masetti, A Cavalli, F De Ponti Medicinal research reviews 25 (2), 133-166, 2005 | 356 | 2005 |
| Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics M Tonini, L Cipollina, E Poluzzi, F Crema, GR Corazza, F De Ponti Alimentary pharmacology & therapeutics 19 (4), 379-390, 2004 | 355 | 2004 |
| Inflammatory neuropathies of the enteric nervous system R De Giorgio, S Guerrini, G Barbara, V Stanghellini, F De Ponti, ... Gastroenterology 126 (7), 1872-1883, 2004 | 336 | 2004 |
| QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience F De Ponti, E Poluzzi, N Montanaro European journal of clinical pharmacology 56, 1-18, 2000 | 314 | 2000 |
| Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome C Cremon, G Carini, B Wang, V Vasina, RF Cogliandro, R De Giorgio, ... Official journal of the American College of Gastroenterology| ACG 106 (7 …, 2011 | 293 | 2011 |
| Enteric neuroplasticity evoked by inflammation V Vasina, G Barbara, L Talamonti, V Stanghellini, R Corinaldesi, M Tonini, ... Autonomic Neuroscience 126, 264-272, 2006 | 254 | 2006 |
| Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS) E Poluzzi, E Raschi, C Piccinni, F De Ponti Data mining applications in engineering and medicine, 2012 | 247 | 2012 |
| Pharmacology of serotonin: what a clinician should know F De Ponti Gut 53 (10), 1520-1535, 2004 | 231 | 2004 |
| Irritable bowel syndrome: new agents targeting serotonin receptor subtypes F De Ponti, M Tonini Drugs 61, 317-332, 2001 | 231 | 2001 |
| Cardiac adverse effects of gastrointestinal prokinetics Tonini, D Ponti, D Nucci, Crema Alimentary pharmacology & therapeutics 13 (12), 1585-1591, 1999 | 227 | 1999 |
| Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy E Raschi, V Vasina, MG Ursino, G Boriani, A Martoni, F De Ponti Pharmacology & therapeutics 125 (2), 196-218, 2010 | 225 | 2010 |
| Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus F De Ponti, E Poluzzi, N Montanaro European journal of clinical pharmacology 57, 185-209, 2001 | 216 | 2001 |
| The β3-adrenoceptor as a therapeutic target: current perspectives MG Ursino, V Vasina, E Raschi, F Crema, F De Ponti Pharmacological research 59 (4), 221-234, 2009 | 202 | 2009 |
| Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective E Poluzzi, C Piccinni, E Raschi, A Rampa, M Recanatini, F De Ponti Current medicinal chemistry 21 (4), 417-436, 2014 | 187 | 2014 |
| Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies G Roberto, E Raschi, C Piccinni, V Conti, L Vignatelli, R D’Alessandro, ... Cephalalgia 35 (2), 118-131, 2015 | 180 | 2015 |
| The hERG K+ channel: target and antitarget strategies in drug development E Raschi, V Vasina, E Poluzzi, F De Ponti Pharmacological research 57 (3), 181-195, 2008 | 178 | 2008 |
| Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. E Poluzzi, E Raschi, D Motola, U Moretti, F De Ponti Drug safety 33 (4), 303-314, 2010 | 174 | 2010 |
| Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS) E Poluzzi, E Raschi, U Moretti, F De Ponti Pharmacoepidemiology and drug safety 18 (6), 512-518, 2009 | 174 | 2009 |
Cesare CremonDepartment of Clinical Medicine and Centre for Applied Biomedical Research, University of Bologna, Bologna, Italyaosp.bo.it의 이메일 확인됨